Rapid progression of prostate cancer in men with a BRCA2 mutation.
Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients. In this study, we compared survival of men with a BRCA2 mutation and prostate cancer with that of men with a BRCA1 mutation and prostate cancer. We obtained the age at diagnosis, age at death or current age from 182 men with prostate cancer from families with a BRCA2 mutation and from 119 men with prostate cancer from families with a BRCA1 mutation. The median survival from diagnosis was 4.0 years for men with a BRCA2 mutation vs 8.0 years for men with a BRCA1 mutation, and the difference was highly significant (P<0.01). It may be important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation.
Narod
S A
SA
Women's College Research Institute, 790 Bay Street, 7th Floor, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada. steven.narod@wchospital.ca
Neuhausen
S
S
Vichodez
G
G
Armel
S
S
Lynch
H T
HT
Ghadirian
P
P
Cummings
S
S
Olopade
O
O
Stoppa-Lyonnet
D
D
Couch
F
F
Wagner
T
T
Warner
E
E
Foulkes
W D
WD
Saal
H
H
Weitzel
J
J
Tulman
A
A
Poll
A
A
Nam
R
R
Sun
P
P
Danquah
Jessica
J
Domchek
Susan
S
Tung
Nadine
N
Ainsworth
Peter
P
Horsman
Douglas
D
Kim-Sing
Charmaine
C
Maugard
Christine
C
Eisen
Andrea
A
Daly
Mary
M
McKinnon
Wendy
W
Wood
Marie
M
Isaacs
Claudine
C
Gilchrist
Dawna
D
Karlan
Beth
B
Nedelcu
Raluca
R
Meschino
Wendy
W
Garber
Judy
J
Pasini
Barbara
B
Manoukian
Siranoush
S
Bellati
Christina
C
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018450:Disease Progression; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology